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Abstract The close correlation observed between matrix
metalloproteinase 2 (MMP-2) activation and metastatic pro-
gression in various tumors suggests that MMP-2 is a ‘master
switch’ triggering tumor spread. Recently, membrane type 1
MMP (MT1-MMP) was identified as a potential physiological
activator of MMP-2. Like all other MMPs, MT1-MMP
possesses a pro-domain which must be removed for the enzyme
to acquire its catalytic potential. The presence of a typical
recognition motif (RXKR) for the furin-like convertases at the
end of its pro-domain suggests a potential role for these
proteinases in MT1-MMP processing. In order to evaluate the
implication of furin in pro-MT1-MMP processing, we treated
HT1080 cells with a synthetic furin inhibitor and monitored their
ability to activate pro-MMP-2 as well as their invasive potential.
Our results demonstrated that the furin inhibitor decreased pro-
MT1-MMP processing as well as pro-MMP-2 activation and
cell invasiveness. Therefore, our data bring further evidence that
furin is a key factor in the maturation of MMPs associated with
the invasive and metastatic potential of tumor cells.
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1. Introduction
Tumor invasion and metastasis represent a multistep proc-
ess that depends on the activity of many proteins [1]. Proteo-
lytic degradation of the extracellular matrix (ECM) compo-
nents is a central event of this process. More speci¢cally, the
ability to penetrate the basement membrane (BM) is associ-
ated with an increased potential for metastasis. Indeed, BM
are present at key points in the metastatic cascade: escape
from the primary tumor in epithelial malignancies, intravasa-
tion and extravasation during hematogenous dissemination as
well as perineural and muscular invasion require BM breach-
ing [2].
Several classes of proteinases, including serine proteinases,
cysteine proteinases and matrix metalloproteinases (MMPs),
have been implicated in tumor cell invasion process [3].
Among these di¡erent proteinases, MMPs appear to be pri-
marily responsible for much of the ECM degradation ob-
served during invasive processes. MMP-2 (also known as ge-
latinase A or 72-kDa type IV collagenase) and MMP-9 (also
known as gelatinase B or 92-kDa type IV collagenase) has
been frequently associated with the invasive and metastatic
potential of tumor cells [1,4^6]. In general, MMPs are secreted
in a latent form (pro-MMP) requiring proteolytic processing
in the N-terminal region in order to become catalytically ac-
tive [7]. This proteolytic maturation is essentially mediated by
serine proteinases (including plasmin and trypsin) or some
activated MMPs (stromelysin). Unlike the other MMPs,
pro-MMP-2 appears refractive to these ‘classical’ activators
[8,9]. Several reports have emphasized the involvement of a
plasma membrane-dependent mechanism of activation for
pro-MMP-2 [9^12]. In this context, Sato and coworkers [13]
have recently discovered MT1-MMP (for membrane type 1
MMP/MMP-14), a novel MMP possessing a hydrophobic
C-terminal transmembrane domain overexpression of which
induces pro-MMP-2 maturation [13^16], indicating that
MT1-MMP is a physiological activator of MMP-2. In addi-
tion to its activating capacity, MT1-MMP also acts as a re-
ceptor for MMP-2 [17], focusing MMP-2 activity to the vicin-
ity of the cell surface, thus resulting in an increased rate of
substrate cleavage [18]. Collectively, these data strongly sug-
gest a key involvement of MT1-MMP during invasive proc-
esses.
A peculiar characteristic of MT1-MMP (also shared by
stromelysin-3/MMP-11) is the presence of a 11-amino acid
insertion in the propeptide at the junction with the catalytic
domain of the latent enzyme. The insertion contains a con-
served RXKR recognition motif for a group of transmem-
brane serine proteinases of the subtilisin family termed fur-
in/PACE/kex-2-like proteinases [19], suggesting a potential
involvement of these proteinases in pro-MT1-MMP process-
ing [13]. In agreement with this proposal, di¡erent reports
brought evidence that furin was able to cleave transmem-
brane-deletion mutants of MT1-MMP [20^22]. In contrast
with these soluble mutants, wild type enzyme appeared resist-
ant to furin activation. In addition, pro-MT1-MMP induced
pro-MMP-2 activation, suggesting that furin-induced process-
ing of MT1-MMP is not a prerequisite for pro-MMP-2 acti-
vation [20].
In an attempt to clarify the putative implication of furin in
pro-MT1-MMP processing, we treated HT1080 cells with a
synthetic furin inhibitor and monitored the ability of these
cells to activate pro-MMP-2 as well as their invasive potential.
Our results demonstrate that the furin inhibitor reduces the
level of mature MT1-MMP, which is paralleled by a decrease
in pro-MMP-2 activation as well as in cell invasiveness.
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Therefore, our data support the concept that pro-MT1-MMP
is processed in vivo via a furin-dependent mechanism.
2. Materials and methods
2.1. Cell culture
HT1080 human ¢brosarcoma cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
calf serum (FCS), penicillin-streptomycin (100 IU/ml-100 Wg/ml),
2 mM glutamine and 10 mM HEPES bu¡er at 37‡C in a humid
atmosphere (5% CO2 and 95% air). All culture reagents were
purchased from Gibco-BRL.
2.2. Coating of culture wells with type IV collagen
96-well plates (Falcon, Becton-Dickinson) and 6.5-mm polycarbon-
ate ¢lters (8 Wm pore size) of Transwell cell culture chamber inserts
(Costar) were coated with 100 Wl of type IV collagen puri¢ed from
human placenta (kindly provided by Dr. H.W. Krell, Boehringer
Mannheim, Penzberg, Germany) diluted at 200 Wg/ml in phosphate-
bu¡ered saline (PBS). Coats were left to air-dry overnight in a laminar
£ow hood under UV light. Uniformity of the coating was assessed by
Coomassie blue staining. Before use, coated plates and inserts were
washed twice with water and incubated for 1 h in serum-free DMEM
at 37‡C.
2.3. Preparation of conditioned medium (CM) and cell lysates (CL)
HT1080 cells exponentially growing in T-75 £asks (Nunc, Costar)
were collected by trypsin-EDTA treatment, washed with serum-con-
taining medium and allowed to recover from trypsinization for at least
30 min at 37‡C. Cells were then washed twice in serum-free DMEM
and diluted in the same medium supplemented with 0.1% BSA (frac-
tion V, Sigma) to a density of 3U105 cells/ml. This suspension was
plated in type IV collagen-coated 96-well plates (see above), 200 Wl/
well, and cultured for 48 h in the presence of the synthetic furin
inhibitor Dec-Arg-Val-Lys-Arg-CH2Cl [23] at concentrations varying
from 0 to 100 WM. The resultant culture supernatants were collected
and stored at 320‡C. Cell monolayers were washed once with 100 Wl
serum-free DMEM and extracted in 50 Wl of Ripa bu¡er (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% Nonidet P40, 1% Triton X-
100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate [SDS],
5 mM iodoacetamide, 2 mM phenylmethylsulfonyl £uoride) for 2 h
at 4‡C.
2.4. Gelatin zymography
Analysis of gelatinolytic activities in CM and CL was performed by
gelatin zymography. Samples (10 Wl) of CM and CL were mixed with
an equal volume of sample bu¡er (62.5 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, 0.1% bromophenol blue) and subjected to electro-
phoresis without boiling on 10% acrylamide gels containing 0.1%
gelatin. Gels were run at 10 mA, washed in 2% Triton X-100 for 1 h
and incubated at 37‡C for 16 h in activation bu¡er (50 mM Tris-HCl,
pH 7.4, 200 mM NaCl, 5 mM CaCl2 and 0.02% NaN3). After staining
with Coomassie brilliant blue R-250, the gelatinolytic activities were
detected as clear bands against the blue background. The relative
proportions of the gelatinolytic bands corresponding to the di¡erent
forms of gelatinase A were evaluated by scanning densitometry using
a GS-700 Imaging Densitometer (Bio-Rad, Hercules, CA) equipped
with Molecular Analyst software. Results are expressed as relative
percentages of total gelatinase A activity.
2.5. Immunoblotting assay for MT1-MMP
For immunoblotting, samples of CL were mixed with an equal
volume of sample bu¡er with reducing agent (700 mM 2-mercapto-
ethanol), boiled for 5 min, and subjected to electrophoresis on 8%
polyacrylamide gels. The proteins were electrically transferred to ni-
trocellulose membranes (Hybond-C extra, Amersham) using a semi-
dry blotting (Bio-Rad). The membranes were blocked with PBS con-
taining 2% (w/v) BSA (fraction V, Across) and 0.1% (v/v) Tween 20
(PBS-BSA-Tween) at room temperature for 60 min and then probed
for 16 h at 4‡C with two distinct monoclonal antibodies (mAbs): mAb
1E12 directed against the N-terminal pro-domain of MT1-MMP and
mAb 2D7 against the hemopexin-like domain of MT1-MMP (kindly
provided by Dr. P. Basset, IGBMC, Illkirch, France). The ¢nal con-
centrations of both mAbs were 5 and 20 Wg/ml, respectively, in PBS-
BSA-Tween. After extensive washing with PBS containing 0.1%
Tween 20, the membranes were reprobed with peroxidase-conjugated
goat anti-mouse IgG (Dako, Denmark) diluted 1000-fold in PBS-
BSA-Tween for 30 min at room temperature and developed with
ECL Western blotting detection reagent (Amersham).
2.6. Invasion assay
The potential in£uence of the furin inhibitor (100 WM) on HT1080
cell invasion and migration was assayed using Transwell cell culture
inserts (Costar). For chemoinvasion assays, type IV collagen-coated
membranes (see above) were used whereas uncoated membranes were
employed for chemotaxis assays. Lower wells of the chambers con-
tained DMEM supplemented with 20% FCS and 1% BSA (fraction V,
ICN) as chemoattractant. The upper wells were seeded with 6U104
cells prepared as described above. Chambers were subsequently incu-
bated for 48 h (in order to maintain a chemotactic gradient, media
from both lower and upper wells were renewed after 24 h) and 4 h (for
chemoinvasion and chemotaxis assays, respectively), in a humid at-
mosphere at 37‡C. After incubation, ¢lters were removed from the
chambers, ¢xed in 4% paraformaldehyde for 15 min, permeabilized
for 10 min in methanol (320‡C) and stained with giemsa (4%). The
upper surface of the ¢lters was scrapped with a cotton swab and cells
having reached the lower surface of the ¢lters were visually counted
using a light microscope (Vanox AH3, Olympus) at 400-fold magni-
¢cation. At least 20 random ¢elds were counted per ¢lter. Each ex-
periment was repeated twice.
2.7. Cytotoxicity assay
In order to assess the potential in£uence of the furin inhibitor on
cell metabolism and/or proliferation, cells were plated on type IV
collagen-coated 96-well plates in the same culture conditions as de-
scribed for the preparation of CM (see above) and incubated for 48 h
in the presence of di¡erent concentrations of the inhibitor (medium
renewal occurred after 24 h). Media were subsequently replaced by
100 Wl of DMEM supplemented with 10% WST-1 (Boehringer Mann-
heim) and plates were incubated for 2 h at 37‡C. Cellular metabolism
was determined by measuring the absorbance of the medium at
450 nm (with a reference ¢lter of 595 nm) on a microtiter plate reader
(Multiscan MS, Labsystems, Finland). At the concentrations tested
(0^100 WM), the synthetic furin inhibitor did not signi¢cantly a¡ect
cellular metabolism and/or proliferation (data not shown).
2.8. Statistical analysis
Statistical analysis of the results was performed using Student’s
t-test. Di¡erences were considered as statistically signi¢cant for P
values lower than 0.05.
3. Results
3.1. E¡ect of the synthetic furin inhibitor on MMP-2 activation
by HT1080 cells
When conditioned medium of HT1080 cells cultured for 48
h on type IV collagen was analyzed by gelatin zymography,
four major gelatinolytic bands of 92 kDa, 66 kDa, 62 kDa
and 59 kDa were detected (Fig. 1A, lane 1). These bands
corresponded to the inactive proforms of MMP-9 (92 kDa)
and MMP-2 (66 kDa), as well as the processed forms of
MMP-2: the 62-kDa intermediate and the fully active 59-
kDa species. Addition of increasing concentrations of the syn-
thetic furin inhibitor (see Section 2) for 48 h resulted in a
dose-dependent reduction of the secretion of both intermedi-
ate (62-kDa) and mature (59-kDa) MMP-2 forms, concur-
rently with a gradual increase in pro-MMP-2 level (Fig.
1A,B). It is worth noting that even at the highest concentra-
tion (100 WM) the inhibitor failed to completely suppress pro-
MMP-2 processing (Fig. 1A, lane 5).
3.2. MT1-MMP processing is modulated by the furin inhibitor
To further explore if the drastic reduction of pro-MMP-2
activation observed in the presence of the furin inhibitor was
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correlated with a decreased level of active MT1-MMP, we
analyzed the pattern of produced MT1-MMP. Cell lysates
from HT1080 cells, treated or not for 48 h with the highest
concentration of the furin inhibitor (100 WM), were analyzed
by Western blotting using two distinct mAbs directed against
the pro- (mAb 1E12) and the hemopexin-like (mAb 2D7)
domains. Lysates from COS cells transiently transfected to
overexpress MT1-MMP were used as a positive control [24].
Lysates of untreated HT1080 cells contained four di¡erent
immunoreactive proteins: a doublet composed of 66-kDa
and 63-kDa species, both recognized by mAb 1E12 (Fig.
2A, lane 1). This doublet co-migrated with those of MT1-
MMP-transfected COS-1 cell lysates (data not shown). In ad-
dition, a 60-kDa and a faint 43-kDa protein were revealed by
mAb 2D7 (Fig. 2B, lane 1).
Although treatment with the furin inhibitor did not cause
any alteration of the level of the 63-kDa protein (Fig. 2A, lane
2), the amounts of 60-kDa and 43-kDa proteins were signi¢-
cantly reduced, the latter being nearly undetectable (it should
be noted that the potential presence of already matured MT1-
MMP species at the cell surface before the addition of the
furin inhibitor most probably underestimates its e¡ectiveness).
In contrast, the expression of the 66-kDa form was noticeably
increased (Fig. 2B, lane 2). These data demonstrate that, in
the experimental conditions used, treatment of cells with a
synthetic furin inhibitor results in an accumulation of unproc-
essed forms, which strongly suggests a decreased pro-MT1-
MMP maturation.
3.3. Furin inhibitor reduces HT1080 invasiveness
To determine whether the presence of activated MT1-
MMP contributes to the invasive behavior of HT1080 cells,
we measured the ability of cells treated or not with the furin
inhibitor to breach and to invade through type IV collagen-
coated Transwell cell culture inserts. In the absence of furin
inhibitor, cells were able to process pro-MMP-2, which was
subsequently released in the culture medium (Fig. 3B, Con-
trol) or bound to type IV collagen and/or cell surface recep-
tors (Fig. 3C, Control). In these conditions, the cells readily
dissolve the collagen layer and migrate through the ¢lter (Fig.
3A, Control). Addition of the furin inhibitor dramatically
reduced the amount of both secreted and bound active
MMP-2 (Fig. 3B,C, Furin Inhibitor), and decreased by 5-
fold the cell invasiveness (Fig. 3A, Furin Inhibitor;
P = 0.0003). In contrast, cell migration through uncoated ¢l-
ters was not signi¢cantly a¡ected (P = 0.51) (as measured in
the chemotaxis assay, Fig. 3A). The degree of invasion inhib-
ition obtained here with the furin inhibitor was similar to
those observed with recombinant TIMP-2 or synthetic
broad-spectrum MMP inhibitors (such as GI129471 or BB-
94), both treatments preventing pro-MMP-2 activation
(manuscript in preparation).
4. Discussion
So far, MMP-2 overexpression by tumor cells and/or their
associated stroma has been considered a key event associated
with tumor progression and metastasis (see [25], for review).
Nevertheless, even if the overproduction of the pro-enzyme
appears necessary for the acquisition of an invasive pheno-
type, it is not by itself a su⁄cient criterion [26]. Indeed, most
MMPs are produced as latent zymogens in which catalytic
activity is tightly regulated. Regulation involves both the con-
trol of zymogen activation and the inhibition of the active
enzyme by speci¢c inhibitors such as TIMPs. In this context,
the close correlation observed between MMP-2 activation and
metastatic progression in various tumors [27^29] suggests that
MMP-2 activator is a ‘master switch’ triggering tumor spread.
Recently, Sato and coworkers identi¢ed MT1-MMP as a po-
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Fig. 2. In£uence of furin inhibitor on MT1-MMP processing.
HT1080 cells were cultured for 48 h on type IV collagen in the ab-
sence (lane 1) or presence (lane 2) of furin inhibitor (100 WM). Cell
extracts were analyzed by Western blotting using mAb 1E12
directed against the pro-domain of MT1-MMP (A) and mAb 2D7
directed against the hemopexin-like domain of MT1-MMP (B).
Fig. 1. Activation of pro-MMP-2 by HT1080 cells treated with in-
creasing concentrations of furin inhibitor. Cells were cultured for 48
h on type IV collagen in the absence (lane 1) or presence of furin
inhibitor: 10 WM (lane 2), 25 WM (lane 3), 50 WM (lane 4) and 100
WM (lane 5). A: Zymographic analysis of conditioned medium. B:
Quanti¢cation of pro-MMP-2 activation by scanning densitometry
of the gel depicted in A. The relative proportions of MMP-2 pro-
(66-kDa; hatched bar), intermediate (62-kDa; white bar), and ma-
ture (59-kDa; black bar) forms is expressed in percent of total
MMP-2.
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tential physiological activator of MMP-2 [13]. Accordingly,
expression of this membrane-associated MT1-MMP has
been shown to mediate pro-MMP-2 activation as well as to
stimulate in vitro invasiveness of di¡erent cell lines. Moreover,
the expression of elevated levels of MT1-MMP in tumor sam-
ples in which MMP-2 is activated suggests that MT1-MMP is
actually involved in MMP-2 processing in vivo [17,30^33].
Like all other known MMPs, MT1-MMP possesses a pro-
domain that confers latency which must be removed for the
enzyme to acquire its catalytic potential. The presence of a
typical recognition motif (RXKR) for furin-like serine pro-
teinases between the pro- and catalytic domains of MT1-
MMP would suggest a potential role for these proteinases in
MT1-MMP maturation [13]. However, by using transfected
cell lines overexpressing di¡erent MT1-MMP forms, some
authors showed that only soluble (obtained by deletion of
the transmembrane region of the protein) and not mem-
brane-anchored forms of MT1-MMP were e⁄ciently proc-
essed by furin [20^22]. In contrast to soluble pro-MT1-
MMP, which was unable to activate MMP-2 before being
processed by furin [21], membrane-bound pro-MT1-MMP ef-
¢ciently activated MMP-2 [20]. These data contrasted with the
isolation by Strongin and coworkers of an activated form of
membrane-associated MT1-MMP from TPA-stimulated
HT1080 cells that readily activated MMP-2 [10]. These con-
troversial observations prompted us to examine the potential
role(s) of furin in MT1-MMP activation in an intact cell sys-
tem. For this purpose, HT1080 cells were treated with a syn-
thetic furin inhibitor [23] previously shown to block the furin-
dependent processing of pro-stromelysin-3 [34].
Western blot analysis of cell lysates obtained from HT1080
cells cultured on type IV collagen revealed the presence of
di¡erent immunoreactive MT1-MMP species corresponding
to a 63-kDa proform [13,20] as well as a 60-kDa protein
previously identi¢ed as activated MT1-MMP [10]. Additional
bands of 66 and 43 kDa were also detected. The 43-kDa form
has been proposed to be a proteolytic fragment of either the
63-kDa or the 60-kDa form. It is worth noting that the oc-
currence of this 43-kDa species has been correlated with pro-
MMP-2 activation. However, whether this species actively
participates in MMP-2 processing remains unknown [35].
Consistent with this correlation, we showed that our cells
e⁄ciently activated pro-MMP-2 through a typical two-step
process, previously shown to be MT1-MMP-dependent
[13,15]. In the presence of the furin inhibitor, the capacity
of HT1080 cells to process pro-MMP-2 was dramatically im-
paired, as judged by the almost complete disappearance of
both intermediate and mature forms of MMP-2. Our immu-
noblotting data obtained from the corresponding cell lysates
revealed that the inhibition of furin clearly reduced the proc-
essing of pro-MT1-MMP into both the 60-kDa and 43-kDa
forms, the latter being almost undetectable. This observation
further supports the putative relationship that could link pro-
MMP-2 activation and the presence of the 43-kDa form of
MT1-MMP in cell lysates. While the inhibition of furin did
not alter the amount of produced 63-kDa pro-MT1-MMP, a
signi¢cant increase of the 66-kDa form was noted. The exact
nature of this form is actually unknown. However, it can be
speculated that this higher molecular weight species represents
a post-translationally modi¢ed form of the 63-kDa pro-MT1-
MMP which is subsequently processed by furin during its
secretion. A similar process has been previously described
during stromelysin-3 maturation [34]. Altogether, these ¢nd-
ings indicate that furin or furin-like convertases are indeed
involved in the activation mechanism of pro-MT1-MMP.
Moreover, even if the furin inhibitor failed to completely pre-
vent the appearance of activated MT1-MMP species, the ma-
turation of pro-MMP-2 was dramatically inhibited, thus con-
¢rming that MMP-2 processing requires activated MT1-
MMP.
In order to further investigate the in£uence of the inhibition
of furin on cell invasiveness, chemoinvasion assays through
type IV collagen-coated ¢lters were performed. Our results
clearly demonstrate that the ability of HT1080 cells to de-
grade and subsequently invade through type IV collagen
was greatly reduced by the furin inhibitor. This impaired in-
vasiveness is most probably the consequence of the reduced
amount of active MMP-2. In addition, activated MT1-MMP
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Fig. 3. Furin inhibitor reduces HT1080 invasiveness. A: HT1080
chemoinvasion (hatched bar) and chemotaxis (white bar) were eval-
uated in Transwell cell culture inserts coated or not with type IV
collagen, respectively. HT1080 cells were seeded in the absence (con-
trol) or presence of furin inhibitor (100 WM) and the number of
cells that have migrated was determined by visually counting the
number of cells present on the lower side of the ¢lters (see Section
2). Results are expressed as percentages of the migration of control
cells. In order to monitor the activation status of MMP-2 during
the invasion assay, conditioned media (B) and cell extracts (C) from
the invasion experiments were collected and analyzed by gelatin zy-
mography. The relative proportions of the pro- (66-kDa; white bar)
and activated (62-kDa and 59-kDa; hatched bar) forms of MMP-2
were determined from scanning densitometry data and are expressed
as percent of total MMP-2.
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also has the capacity to directly digest several components of
the ECM [21,36], thus facilitating cell invasion.
Taken together, these data bring further evidence that furin
is a key factor in the maturation of MMPs (MT1-MMP and
MMP-2) associated with the invasive and metastatic potential
of tumor cells.
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